BioPharma Credit Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	12.59	5.62	135.05	120.53	94.71
Cash & Short-Term Investments	12.59	5.62	135.05	120.53	94.71
Cash Growth	123.97%	-95.84%	12.05%	27.26%	-51.00%
Accounts Receivable	53.46	31.71	20.23	19.73	9.59
Other Receivables	0.14	0.08	0.09	0.11	0.42
Receivables	53.6	31.8	20.32	19.84	10.01
Total Current Assets	66.19	37.42	155.37	140.37	104.72
Long-Term Investments	1,102	1,162	1,201	1,224	1,266
Total Assets	1,168	1,200	1,357	1,364	1,371
Accrued Expenses	17.56	16.94	15.87	24.35	6.34
Other Current Liabilities	-	0.95	-	1.95	-
Total Current Liabilities	17.56	17.88	15.87	26.3	6.34
Long-Term Unearned Revenue	-	0.06	-	0.26	0.56
Total Liabilities	17.56	17.94	15.87	26.56	6.9
Common Stock	13.74	13.74	13.74	13.74	13.74
Additional Paid-In Capital	607.13	607.13	607.13	607.13	607.13
Retained Earnings	530	560.81	720	716.59	742.85
Shareholders' Equity	1,151	1,182	1,341	1,337	1,364
Total Liabilities & Equity	1,168	1,200	1,357	1,364	1,371
Net Cash (Debt)	12.59	5.62	135.05	120.53	94.71
Net Cash Growth	123.97%	-95.84%	12.05%	27.26%	-51.00%
Net Cash Per Share	0.01	0.00	0.10	0.09	0.07
Filing Date Shares Outstanding	1,129	1,140	1,254	1,319	1,374
Total Common Shares Outstanding	1,129	1,186	1,303	1,319	1,374
Working Capital	48.63	19.53	139.5	114.06	98.38
Book Value Per Share	1.02	1.00	1.03	1.01	0.99
Tangible Book Value	1,151	1,182	1,341	1,337	1,364
Tangible Book Value Per Share	1.02	1.00	1.03	1.01	0.99